DelveInsight’s comprehensive Dengue Fever market report forecasts strong growth across the 7MM through 2032, highlighting key players including Visterra, Takeda, Codagenix, Atea Pharmaceuticals, Abivax, Janssen R&D, and Plex Pharmaceuticals. These companies are driving innovation with next-generation dengue therapeutics and vaccines to meet the growing global health need in this...

Perspectives du marché des tumeurs neuroendocrines gastro-intestinales (TNE-GI) jusqu'en 2034 DelveInsightRapport sur le marché des tumeurs neuroendocrines gastro-intestinales (TNE-GI)propose une analyse complète des 7 principaux marchés mondiaux jusqu'en 2034, mettant en lumière des entreprises clés telles queNovartis, Ipsen, ITM Solucin, Camurus, et...

DelveInsight’s comprehensive Dengue Fever market report forecasts strong growth across the 7MM through 2032, highlighting key players including Visterra, Takeda, Codagenix, Atea Pharmaceuticals, Abivax, Janssen R&D, and Plex Pharmaceuticals. These companies are driving innovation with next-generation dengue therapeutics and vaccines to meet the growing global health need in this...

Type 1 Diabetes Market Outlook: Emerging Therapies Reshape Future Opportunities DelveInsight’s latest Type 1 Diabetes Market Report highlights strong growth potential through 2034, led by disease-modifying breakthroughs like TZIELD and advances in stem-cell and weekly insulin therapies. The US dominates with 89% market share, followed by the EU4, UK, and Japan. Leading innovators include...

DelveInsight's Tuberculosis Market Forecast 2032 DelveInsight's Tuberculosis Market Forecast 2032 projects significant growth across the 7MM, driven by leading companies such as Biofabri, GlaxoSmithKline, Otsuka Pharmaceutical, Sequella Inc., Global Alliance for TB Drug Development, and Spero Therapeutics. These players are advancing innovative therapies - such as MTBVAC, GSK3036656, and RUTI -...

DelveInsight's Tuberculosis Market Forecast 2032 DelveInsight's Tuberculosis Market Forecast 2032 projects significant growth across the 7MM, driven by leading companies such as Biofabri, GlaxoSmithKline, Otsuka Pharmaceutical, Sequella Inc., Global Alliance for TB Drug Development, and Spero Therapeutics. These players are advancing innovative therapies - such as MTBVAC, GSK3036656, and RUTI -...

The idiopathic inflammatory myositis (IIM) treatment market is poised for substantial growth, fueled by the development of innovative targeted therapies and rising awareness of this rare autoimmune disorder. Leading companies, including Octapharma, Pfizer, Mitsubishi Tanabe Pharma, AstraZeneca, Priovant Therapeutics, and CSL, are advancing the treatment landscape with promising therapies that...

The IgA Nephropathy (IgAN) treatment market is set for significant expansion, fueled by the emergence of innovative therapies and the rising prevalence of this chronic kidney disorder. Key players, including Calliditas Therapeutics AB, Travere Therapeutics, Inc., Omeros, Novartis Pharmaceuticals, Chinook Therapeutics, Inc., and Vera Therapeutics, are actively reshaping the IgAN treatment...

The Fuchs Endothelial Corneal Dystrophy (FECD) market is projected to witness robust growth in the coming years, driven by the development of innovative non-surgical therapies and substantial research investments from key players such as Kowa Pharmaceuticals, Trefoil Therapeutics, Santen, ActualEyes, Alcon, Emmecell, AJL Ophthalmic SA, Massachusetts Eye and Ear, KeraMed, Inc., and Presbia Plc,...

CinCor Pharma's baxdrostat has shown statistically significant reductions in systolic blood pressure in patients with hard-to-control hypertension, according to full results from the BaxHTN Phase III trial announced on August 30, 2025. DelveInsight examines the market impact and evolving competitive landscape in the hypertension treatment sector.   Hypertension Market Insights,...